Loxo Oncology Announces Positive Top-Line Results from Independent Review Committee Assessment of Larotrectinib Dataset
– 75% Overall Response Rate by Independent Review; 80% Overall Response Rate by Investigator Assessment – STAMFORD, Conn., Oct. 18, 2017 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly …